Well Referenced

Tag: premenopausal women

Short-term oral progesterone administration antagonizes the effect of transdermal estradiol on endothelium-dependent vasodilation in young healthy women

This study examined the effects of short-term oral micronized progesterone on the vascular benefits of transdermal estradiol in 17 premenopausal women. Participants underwent hormone suppression with a gonadotropin-releasing hormone antagonist for 10-12 days, followed by supplementation with either 200 mg oral micronized progesterone or 0.1 mg transdermal estradiol. The results

Read More »
June 26, 2025 No Comments

Testosterone in Female Depression: A Meta-Analysis and Mendelian Randomization Study

This meta-analysis and Mendelian randomization study explores the relationship between serum testosterone levels and depression in women. While the meta-analysis indicates a significant association, particularly in premenopausal women, the Mendelian randomization analysis does not establish a causal link. These findings suggest that testosterone levels may act as a marker rather

Read More »
June 26, 2025 No Comments

Influence of estrogen-progestin treatment on back pain and disability among slim premenopausal women with low lumbar spine bone mineral density. A 2-year placebo-controlled randomized trial

This randomized controlled trial examined the effects of estrogen-progestin therapy on back pain and functional disability in slim premenopausal women with low lumbar spine bone mineral density (BMD). Among 48 participants, those receiving hormone therapy experienced significant reductions in nighttime back pain (p < 0.001) and Oswestry disability scores (p

Read More »
June 26, 2025 No Comments

Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder

This article reviews the efficacy and safety of flibanserin, a treatment for generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women. The review found that flibanserin improved satisfying sexual events and sexual function, as measured by the Female Sexual Function Index and the Female Sexual Distress Scale. However, the

Read More »
June 26, 2025 No Comments

Flibanserin for hypoactive sexual desire disorder in premenopausal women

Flibanserin is a mixed 5-HT1A agonist and 5-HT2A antagonist approved for treating premenopausal women with hypoactive sexual desire disorder (HSDD). It is the first FDA-approved medication for this condition, showing efficacy by increasing the number of satisfying sexual events. However, flibanserin has been associated with side effects, including hypotension and

Read More »
June 26, 2025 No Comments

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

This study evaluated the effect of bremelanotide on sexual arousal and desire in premenopausal women with sexual arousal disorder. Bremelanotide improved both subjective sexual responses and vaginal pulse amplitude compared to a placebo. The treatment was well tolerated, with mild side effects such as nausea and headaches. This research suggests

Read More »
June 26, 2025 No Comments